KRAS mutation in pancreatic cancer

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network...

Celý popis

Podrobná bibliografia

Vydané v:	Seminars in oncology Ročník 48; číslo 1; s. 10
Hlavný autor:	Luo, Ji
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.02.2021
Predmet:	Humans Mutation Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Proto-Oncogene Proteins p21(ras) - genetics Signal Transduction - genetics MAPK pathway G12C KRAS Targeted therapy Pancreatic cancer
ISSN:	1532-8708, 1532-8708
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!